Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 20

Showing 20 citing articles:

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Lingping Kong, Fanlu Meng, Ping Zhou, et al.
Science Bulletin (2024) Vol. 69, Iss. 13, pp. 2122-2135
Open Access | Times Cited: 8
Targeted Degradation of HCV Polymerase by GalNAc-Conjugated ApTACs for Pan-Genotypic Antiviral Therapy with High Resistance Barriers
Wei Pan, Sijin Wu, Honglin Zhou, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Multifaceted roles of UFMylation in health and disease
R. Wang, Li Lin, Jun Zhou, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Ye Tian, Maximilian Seifermann, Liana Bauer, et al.
Small (2024) Vol. 20, Iss. 26
Closed Access | Times Cited: 4
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 4
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 11
Targeting protein aggregation for the treatment of neurodegenerative diseases
Qingchao Li, Wei Pan, Jun Zhou, et al.
Medicine Plus (2024) Vol. 1, Iss. 1, pp. 100005-100005
Open Access | Times Cited: 3
Targeted degradation of membrane and extracellular proteins with LYTACs
Yuyang Li, Yang Yang, Renshuai Zhang, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 3
Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis
Ping Zhou, Sai Zhang, Li Lin, et al.
Theranostics (2024) Vol. 14, Iss. 13, pp. 4983-5000
Open Access | Times Cited: 2
Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes
Janarthanan Venkatesan, Dhanashree Murugan, Kalaiarasu Lakshminarayanan, et al.
Pharmacology & Therapeutics (2024) Vol. 263, pp. 108725-108725
Closed Access | Times Cited: 1
Powering Up Targeted Protein Degradation Through Active and Passive Tumour-Targeting Strategies: Current and Future Scopes
Janarthanan Venkatesan, Dhanashree Murugan, Kalaiarasu Lakshminarayanan, et al.
(2024)
Closed Access
Acetyl-CoA Carboxylase Proteolysis-Targeting Chimeras: Conceptual Design and Application as Insecticides
Qi Xu, Hao Feng, Zhong Li, et al.
Journal of Agricultural and Food Chemistry (2024) Vol. 72, Iss. 34, pp. 18809-18815
Closed Access
Aptamer-Hytac Chimeras for Targeted Degradation of SARS-CoV-2 Spike-1
Carme Fàbrega, Núria Gallisà-Suñé, Alice Zuin, et al.
Cells (2024) Vol. 13, Iss. 21, pp. 1767-1767
Open Access
AKT kinases as therapeutic targets
Dalal Hassan, Craig W. Menges, Joseph R. Testa, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access
NIR-responsive gold nanomaterials in photothermal antibacterial therapy: From morphological design to multifunctional platforms
Jing Gong, Qihang Ding, Yujia Shi, et al.
Coordination Chemistry Reviews (2024) Vol. 526, pp. 216348-216348
Closed Access
Development of an Automated Capture-SELEX Device for Efficient Screening of β-Conglycinin Aptamer
Yingming Zhang, Shikun Zhang, Zhiyuan Ning, et al.
Journal of Agricultural and Food Chemistry (2024)
Closed Access
Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits
Linghong Huang, Quan Zhang, Jun Long, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 38-59
Closed Access
Advancing targeted protein degradation modalities
Jerry C. Madukwe
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 743-745
Open Access
Page 1

Scroll to top